Bottom line: Teclistamab-cqyv (Tecvayli) led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results